Cargando…
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set
BACKGROUND: In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to mor...
Autores principales: | Grothey, Axel, Yoshino, Takayuki, Bodoky, Gyorgy, Ciuleanu, Tudor, Garcia-Carbonero, Rocio, García-Alfonso, Pilar, Van Cutsem, Eric, Muro, Kei, Mytelka, Daniel S, Li, Li, Lipkovich, Olga, Hsu, Yanzhi, Sashegyi, Andreas, Ferry, David, Nasroulah, Federico, Tabernero, Josep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922565/ https://www.ncbi.nlm.nih.gov/pubmed/29713498 http://dx.doi.org/10.1136/esmoopen-2018-000347 |
Ejemplares similares
-
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
por: Tabernero, J, et al.
Publicado: (2018) -
Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial
por: Cohn, Allen Lee, et al.
Publicado: (2017) -
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression(†)
por: Obermannová, R., et al.
Publicado: (2016) -
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study
por: Yoshino, T, et al.
Publicado: (2019) -
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
por: Fuchs, Charles S., et al.
Publicado: (2017)